WaveMan
WaveMan · Company
CRVO · Cervomed Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CRVO CervoMed (CRVO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001053691
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter

What the filings say about CRVO

Insiders, 180 days
+$3.0M net bought
1 buyer

CervoMed insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CervoMed Inc. insiders bought a net $3.0M of stock across 22 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BOGER JOSHUA S
Director
BUY
2026-06-15 SECtraded 2026-06-11
955,414
$3.0M
-50.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 53.2% of the 1,795,865 shares held after it.
  • No other insider bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BOGER JOSHUA S bought about $3.0M of CRVO on Jun 11, 2026, the largest insider purchase at the company on our record; 16 funds added in the latest 13F quarter.
Winton Matthew
Chief Commercial and Business
BUY
2025-11-19 SECtraded 2025-11-18
1,500
$11.9K
-75.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 17, 2025.
  • -42.9% median (-42.9% mean) 90-day return after 2 previous buys.
  • The trade is 10.0% of the 15,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial and Business Winton Matthew bought about $11.9K of CRVO on Nov 18, 2025; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
ELDER WILLIAM ROBERT
CFO, GC & Secretary
BUY
2025-11-19 SECtraded 2025-11-18
2,500
$20.8K
-75.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Nov 17, 2025.
  • -37.9% median (-27.6% mean) 90-day return after 4 previous buys.
  • The trade is 20.0% of the 12,500 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO, GC & Secretary ELDER WILLIAM ROBERT bought about $20.8K of CRVO on Nov 18, 2025; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
Winton Matthew
Chief Commercial and Business
BUY
2025-11-19 SECtraded 2025-11-17
3,500
$29.5K
-75.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 14, 2025.
  • The trade is 25.9% of the 13,500 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial and Business Winton Matthew bought about $29.5K of CRVO on Nov 17, 2025; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
Gregoire Sylvie
Director
BUY
2025-11-19 SECtraded 2025-11-17
10,793
$91.3K
-75.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Nov 14, 2025.
  • -33.8% median (-35.3% mean) 90-day return after 3 previous buys.
  • The trade is 0.7% of the 1,484,078 shares held after it.
  • 3 other insiders bought within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gregoire Sylvie bought about $91.3K of CRVO on Nov 17, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 16 funds added in the latest 13F quarter.
22 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 17 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$3.0M over 180 days
+$3.0M of it by a 10%+ holder
more than 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
-58.9% year over year
below 82% of Pharma & Biotech
Margin
-673.1% net margin
below 81% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.6% of the float short (float per yahoo 2026-10-27) · 3.0 days to cover · settled 2026-10-15
more than 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CRVO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-68.4%12M
-68%-32%+4%+40%2025-102025-122026-022026-042026-062026-082026-10 2026-06-11 · BOGER JOSHUA S bought $3.0M2025-11-17 · Gregoire Sylvie bought $91.4K2025-11-17 · ALAM JOHN J bought $91.4K2025-11-17 · Gregoire Sylvie bought $91.3K2025-11-17 · ALAM JOHN J bought $91.3K2025-11-14 · Winton Matthew bought $75.7K2025-11-12 · Gregoire Sylvie bought $40.8K2025-11-12 · ALAM JOHN J bought $40.8K2025-11-13 · Gregoire Sylvie bought $33.4K2025-11-13 · ALAM JOHN J bought $33.4K2025-11-17 · Winton Matthew bought $29.5K2025-11-12 · ELDER WILLIAM ROBERT bought $26.0K2025-11-18 · ELDER WILLIAM ROBERT bought $20.8K2025-11-14 · Gregoire Sylvie bought $12.9K2025-11-14 · ALAM JOHN J bought $12.9K2025-11-14 · Gregoire Sylvie bought $12.8K2025-11-14 · ALAM JOHN J bought $12.8K2025-11-18 · Winton Matthew bought $11.9K2025-11-17 · ELDER WILLIAM ROBERT bought $8.4K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CRVO: institutional holders (13F)

13F holdings, latest reported quarter
Woodline Partners LP
688,987 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
316,202 sh
$980.2K
SABBY MANAGEMENT, LLC
248,880 sh
$771.5K
GEODE CAPITAL MANAGEMENT, LLC
66,923 sh
$207.5K
BlackRock, Inc.
53,845 sh
$166.9K

Congress trades in CRVO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CRVO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CRVO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$60.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$3.3K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity ETF
$10.2K position · as of 2026-05-31
0.0%
Fidelity Extended Market Index Fund
$115.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$204.7K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$23.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Dr. Alam
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.0M
$1.5M
$669.4K
+4%
n/a
2024
$1.0M
$953.3K
$732.5K
-69%
n/a
2023
$1.5M
$1.4M
$467.0K
+1%
n/a
2022
$1.4M
$1.3M
$400.7K
-67%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $3.0M bought by insiders over 180 days, 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CRVO financials

Revenue growth
-58.9%
XBRL, annual
Net margin
-673.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$331.3K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$28.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term debt only, 2017-03-31 (112 months older than the period end); equity 2026-06-30
Cash flow to debt
-50.87x
TTM operating cash flow over long-term debt only, 2017-03-31 (112 months older than the period end)
Return on equity
-107.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-94.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-112.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$12.0M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term debt only, 2017-03-31 (112 months older than the period end), minus cash 2026-06-30
FCF yield
-83.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$4.0M$9.7M$7.1M$0
Operating income-$28.3M-$18.2M-$7.8M-$3.5M
Net income-$27.0M-$16.3M-$2.2M-$5.8M
EPS (diluted)n/an/an/a2,038,891.00
Operating cash flow-$23.4M-$16.5M-$7.4M-$2.6M
Cash$8.2M$9.0M$7.8M$4.1M
SEC XBRL, fiscal years, as known on 2026-10-28

CRVO Stock Sonar score 6/7 axes

Find similar shapesCompare

CRVO ranks highest on insider conviction (74th percentile) and financial health (41st), and lowest on growth (18th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
27
Inputs
  • Return on equity-107.6% · 31 pct, sector of 545
  • Return on assets-94.7% · 26 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-112.2% · 23 pct, sector of 576
Financial health
41
Inputs
  • Debt to equity0.02x · 70 pct, sector of 352
  • Cash flow to debt-50.87x · 11 pct, sector of 371
Growth
18
Inputs
  • Revenue growth, YoY-58.9% · 18 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
74
Inputs
  • Net Form 4 buying (codes P and S), 180d$3.0M · 93 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
28
Inputs
  • Funds adding, latest quarter16 · 28 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
20
Inputs
  • Short interest, % of float+12.6% · 31 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+29.4% · 8 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CRVO filings, in plain words

Are CervoMed insiders buying or selling CRVO?

In the 180 days to 2026-10-28, CervoMed insiders were net buyers, a net $3.0M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, CervoMed insiders were net buyers of CRVO, a net $3.0M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $3.0M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies